1
|
Bilateral breast cancer in a survivor of acute lymphoblastic leukemia: a case report. Med Oncol 2009; 27:481-3. [PMID: 19472087 DOI: 10.1007/s12032-009-9238-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2009] [Accepted: 05/15/2009] [Indexed: 10/20/2022]
Abstract
Although breast cancer is the most common disease for women, bilateral breast cancer is a rare situation. Development of a second malignancy which is the most frightening side effect, may be related with genetic predisposition or cancer treatment. Because our case is a survivor of acute lymphoblastic leukemia, development of bilateral breast cancer which occurs rarely in early ages, is discussed with the help of literature.
Collapse
|
2
|
Tsavaris N, Lazaris A, Kosmas C, Gouveris P, Kavantzas N, Kopterides P, Papathomas T, Arapogiannis G, Zorzos H, Kyriakou V, Patsouris E. Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. Cancer Chemother Pharmacol 2008; 64:391-8. [PMID: 19083133 PMCID: PMC2688619 DOI: 10.1007/s00280-008-0886-4] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2008] [Accepted: 11/21/2008] [Indexed: 11/26/2022]
Abstract
Purpose Human DNA topoisomerases I and II (topo-I and -II) are essential for vital cellular processes such as DNA replication, transcription, translation, recombination, and repair. In the present study, we correlate topo-I and -II expression and outcome after chemotherapy in primary and relapsed colorectal cancer. Patients and methods Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study. All had undergone surgical resection of the primary tumor and received post-operatively 5-FU-based (5FU + Leucovorin, Mayo Clinic regimen) adjuvant chemotherapy. Tumor tissue was collected at the initial operation from the primary tumor and at the time of recurrence (during the second operation following chemotherapy). All tissue samples were analyzed for levels of expression of both topo-I and topo-IIa using standard three-step immunohistochemistry on paraffin sections. Results Forty patients were included. Levels of expression of topo-I and topo-II were higher in malignant cells from tumor recurrences compared to primary tumors (P = 0.0001 for both). There was a statistically significant positive relationship between patients age and levels of topo-I (P = 0.011) and topo-II (P = 0.011) expression. Conclusions The study results reported here underscore the role of topoisomerase expression in colorectal cancer and suggest a potential role in tumor recurrence.
Collapse
Affiliation(s)
- Nicolas Tsavaris
- Medical Oncology Unit, Department of Pathophysiology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens University School of Medicine, 11527 Athens, Greece
| | - Andreas Lazaris
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Christos Kosmas
- Second Department of Medical Oncology, “Metaxa” Cancer Hospital, Piraeus, Greece
| | - Panagiotis Gouveris
- Medical Oncology Unit, Department of Pathophysiology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens University School of Medicine, 11527 Athens, Greece
| | - Nikolaos Kavantzas
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Petros Kopterides
- Medical Oncology Unit, Department of Pathophysiology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens University School of Medicine, 11527 Athens, Greece
| | - Thomas Papathomas
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - George Arapogiannis
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Haralambos Zorzos
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Vassiliki Kyriakou
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Efstathios Patsouris
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|